No price history available.
Key financial summary
Financials in MXN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | MXNm | 4,466 | 3,906 | 3,868 | 4,130 | 4,403 | 4,789 | N/A | N/A |
| Operating profit | MXNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | MXNm | 559 | 1,155 | 950 | 635 | 462 | 540 | N/A | N/A |
| EPS reported | MXN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | MXN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | MXN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | MXN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | MXNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | MXNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | MXNm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | MXN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | MXN | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in MXN| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Médica Sur, S.A.B. de C.V. functions as a leading healthcare provider within Mexico. The institution furnishes a comprehensive array of medical and surgical treatments, including intricate procedures such as bypass and gastric banding, cholecystectomy, inguinal hernia repair, liposculpture, breast augmentation, stereotactic radiosurgery, hip arthroplasty, knee and shoulder arthroscopy, spinal operations, lithiasis removal, and various prostate interventions, notably radical prostatectomy. Beyond these surgical offerings, Médica Sur also extends its services to include advanced radiotherapy, diagnostic imaging, comprehensive health check-ups, and medical insurance solutions. Established in 1966, this entity is headquartered in Mexico City and operates as a subsidiary of Neuco, SA de CV.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Médica Sur, S.A.B. de C.V. (MEDICAB.MX)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Médica Sur, S.A.B. de C.V. functions as a leading healthcare provider within Mexico. The institution furnishes a comprehensive array of medical and surgical treatments, including intricate procedures such as bypass and gastric banding, cholecystectomy, inguinal hernia repair, liposculpture, breast augmentation, stereotactic radiosurgery, hip arthroplasty, knee and shoulder arthroscopy, spinal operations, lithiasis removal, and various prostate interventions, notably radical prostatectomy. Beyond these surgical offerings, Médica Sur also extends its services to include advanced radiotherapy, diagnostic imaging, comprehensive health check-ups, and medical insurance solutions. Established in 1966, this entity is headquartered in Mexico City and operates as a subsidiary of Neuco, SA de CV.